SCHEMBL7138159

SCHEMBL7138159

CCCCCN(C(=O)COCc1ccccc1)S(=O)(=O)CN(CC(C)CC)C(=O)OCc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CCR6 P51684 1/20 0.38
PAX8 Q06710 1/20 0.38
ALDH1A1 P00352 2/20 0.34
CYP3A4 P08684 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CNR2 P34972 1/20 0.34
CCKBR P32239 1/20 0.34
CCR5 P51681 1/20 0.34
CA12 O43570 2/20 0.33
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
CA4 P22748 1/20 0.33
CTRC Q99895 1/20 0.33
CETP P11597 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7140775 0.87 CCR6 (0.43) CCR6PAX8ALDH1A1CYP3A4TSHR
SCHEMBL7138155 0.72 ALDH1A1 (0.34) CCR6PAX8ALDH1A1CYP3A4TSHR
SCHEMBL27990536 0.71 CCR6 (0.66) CCR6PAX8ALDH1A1CYP3A4TSHR
SCHEMBL7797006 0.71 L3MBTL1 (0.45) L3MBTL1
SCHEMBL7132828 0.71 ALDH1A1 (0.39) CCR6PAX8ALDH1A1CYP3A4TSHR
SCHEMBL25628629 0.70 CCR6 (0.64) CCR6PAX8ALDH1A1CYP3A4TSHR
SCHEMBL15508590 0.69 CCR6 (0.63) CCR6PAX8ALDH1A1CYP3A4TSHR
SCHEMBL20147826 0.69 ALDH1A1 (0.50) CCR6PAX8ALDH1A1CYP3A4TSHR
SCHEMBL17275425 0.68 CCR6 (0.61) CCR6PAX8ALDH1A1CYP3A4TSHR
SCHEMBL28271583 0.68 CCR6 (0.58) CCR6PAX8ALDH1A1CYP3A4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030092634-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. 2003-05-15 US disclosed
US-6506733-B1 Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. AXYS PHARMACEUTICALS, INC. 2003-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092634-A1 Novel compounds and compositions as protease inhibitors SERPINB1, HPN, CTRL CCR6 2751/4885PAX8 4614/4885ALDH1A1 3641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.